Search Results for "Jardiance"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Jardiance. Results 11 to 17 of 17 total matches.
See also: empagliflozin
Bexagliflozin (Brenzavvy) — A Fifth SGLT2 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
(Invokana), dapagliflozin
(Farxiga), and empagliflozin (Jardiance) are FDA-approved
to improve cardiac ...
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose
cotransporter 2 (SGLT2) inhibitor, has been
approved by the FDA to improve glycemic control
in adults with type 2 diabetes. It is the fifth SGLT2
inhibitor to be approved in the US for this indication
(see Table 4).
Med Lett Drugs Ther. 2023 Aug 21;65(1683):130-2 doi:10.58347/tml.2023.1683b | Show Introduction Hide Introduction
In Brief: Canagliflozin and Lower Limb Amputations
The Medical Letter on Drugs and Therapeutics • Sep 21, 2020 (Issue 1607)
.
The SGLT2 inhibitors dapagliflozin (Farxiga) and
empagliflozin (Jardiance) have not been associated ...
The FDA has removed a boxed warning from the labeling
of products containing the sodium-glucose co-transporter
2 (SGLT2) inhibitor canagliflozin (Invokana, Invokamet,
Invokamet XR) that described an increased risk of lower
limb amputation associated with use of the drug. Package
inserts for canagliflozin products still contain a standard
warning about a risk of lower limb amputation.
Comparison Chart: SGLT2 Inhibitors (online only)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
ertugliflozin empagliflozin dapagliflozin canagliflozin Jardiance linagliptin Xigduo Synjardy Steglujan ...
View the Comparison Chart: SGLT2 Inhibitors
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 14, 2021 (Issue 1626)
/day8 10 mg once/day 532.80
Empagliflozin – Jardiance 10, 25 mg tabs 10 mg once/day9 10 mg once/day ...
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF ≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF.
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
for chronic heart failure. Med Lett Drugs Ther 2019;
61:49.
4. Empagliflozin (Jardiance) for heart failure ...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension...
Comparison Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
Empagliflozin –
Jardiance (Boehringer
Ingleheim/Lilly)10
10, 25 mg tabs
10 mg once/day
Renal impairment ...
View the Comparison Table: Some Drugs for HFrEF
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
for HF in adults with
CKD at risk of progression
Empagliflozin (Jardiance)
Reduce risk ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.